Processa Pharmaceuticals, Inc.PCSA
Price (close)
$1.85
Market cap
$5.2M
P/E
—
Revenue (TTM)
—
Net income
-$13.4M
Dividend yield
—
1-year total return
-61.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Processa Pharmaceuticals, Inc. does.
Processa Pharmaceuticals, Inc. (“Processa,” “we” or the “Company”) was incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 601 21 st
make available free of charge on or through our Internet website ( http://www.processapharmaceuticals.com ) our Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | — | — | — |
| Net income | -$14.4M | -$11.4M | -$27.4M | -$11.1M | -$11.9M | -$13.6M |
| Free cash flow | — | — | — | -$8.1M | -$11.2M | — |
More on PCSA.
- Processa Pharmaceuticals, Inc. summary
- Processa Pharmaceuticals, Inc. financial statements
- Processa Pharmaceuticals, Inc. key metrics
- Processa Pharmaceuticals, Inc. health scores and style box
- Processa Pharmaceuticals, Inc. earnings
- Processa Pharmaceuticals, Inc. dividends
- Processa Pharmaceuticals, Inc. valuation
- Processa Pharmaceuticals, Inc. ownership and insiders
- Processa Pharmaceuticals, Inc. peers
Figures from Processa Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.